These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

365 related articles for article (PubMed ID: 33994322)

  • 1. The challenge of emerging SARS-CoV-2 mutants to vaccine development.
    Li R; Liu J; Zhang H
    J Genet Genomics; 2021 Feb; 48(2):102-106. PubMed ID: 33994322
    [No Abstract]   [Full Text] [Related]  

  • 2. COVID-19 vaccine breakthrough infections.
    Gupta RK; Topol EJ
    Science; 2021 Dec; 374(6575):1561-1562. PubMed ID: 34941414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variant-proof vaccines - invest now for the next pandemic.
    Burton DR; Topol EJ
    Nature; 2021 Feb; 590(7846):386-388. PubMed ID: 33558746
    [No Abstract]   [Full Text] [Related]  

  • 4. The emerging plasticity of SARS-CoV-2.
    McCormick KD; Jacobs JL; Mellors JW
    Science; 2021 Mar; 371(6536):1306-1308. PubMed ID: 33766871
    [No Abstract]   [Full Text] [Related]  

  • 5. SARS-CoV-2 evolution and vaccines: cause for concern?
    Williams TC; Burgers WA
    Lancet Respir Med; 2021 Apr; 9(4):333-335. PubMed ID: 33524316
    [No Abstract]   [Full Text] [Related]  

  • 6. Sieve analysis to understand how SARS-CoV-2 diversity can impact vaccine protection.
    Rolland M; Gilbert PB
    PLoS Pathog; 2021 Mar; 17(3):e1009406. PubMed ID: 33765086
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7.
    Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD
    Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fast-spreading COVID variant can elude immune responses.
    Callaway E
    Nature; 2021 Jan; 589(7843):500-501. PubMed ID: 33479534
    [No Abstract]   [Full Text] [Related]  

  • 9. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies.
    Collier DA; De Marco A; Ferreira IATM; Meng B; Datir RP; Walls AC; Kemp SA; Bassi J; Pinto D; Silacci-Fregni C; Bianchi S; Tortorici MA; Bowen J; Culap K; Jaconi S; Cameroni E; Snell G; Pizzuto MS; Pellanda AF; Garzoni C; Riva A; ; Elmer A; Kingston N; Graves B; McCoy LE; Smith KGC; Bradley JR; Temperton N; Ceron-Gutierrez L; Barcenas-Morales G; ; Harvey W; Virgin HW; Lanzavecchia A; Piccoli L; Doffinger R; Wills M; Veesler D; Corti D; Gupta RK
    Nature; 2021 May; 593(7857):136-141. PubMed ID: 33706364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.
    Kannan S; Shaik Syed Ali P; Sheeza A
    Eur Rev Med Pharmacol Sci; 2021 Dec; 25(24):8019-8022. PubMed ID: 34982466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation-induced changes in the receptor-binding interface of the SARS-CoV-2 Delta variant B.1.617.2 and implications for immune evasion.
    Baral P; Bhattarai N; Hossen ML; Stebliankin V; Gerstman BS; Narasimhan G; Chapagain PP
    Biochem Biophys Res Commun; 2021 Oct; 574():14-19. PubMed ID: 34425281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
    Rani PR; Imran M; Lakshmi JV; Jolly B; Jain A; Surekha A; Senthivel V; Chandrasekhar P; Divakar MK; Srinivasulu D; Bhoyar RC; Vanaja PR; Scaria V; Sivasubbu S
    J Med Virol; 2021 Jul; 93(7):4163-4165. PubMed ID: 33818797
    [No Abstract]   [Full Text] [Related]  

  • 14. COVID-19 mRNA vaccines.
    Huang Q; Zeng J; Yan J
    J Genet Genomics; 2021 Feb; 48(2):107-114. PubMed ID: 34006471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implication of SARS-CoV-2 Immune Escape Spike Variants on Secondary and Vaccine Breakthrough Infections.
    Ahmad L
    Front Immunol; 2021; 12():742167. PubMed ID: 34804022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to redesign COVID vaccines so they protect against variants.
    Callaway E; Ledford H
    Nature; 2021 Feb; 590(7844):15-16. PubMed ID: 33514888
    [No Abstract]   [Full Text] [Related]  

  • 17. Will SARS-CoV-2 variants of concern affect the promise of vaccines?
    Gupta RK
    Nat Rev Immunol; 2021 Jun; 21(6):340-341. PubMed ID: 33927376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2 B.1.617 Mutations L452R and E484Q Are Not Synergistic for Antibody Evasion.
    Ferreira IATM; Kemp SA; Datir R; Saito A; Meng B; Rakshit P; Takaori-Kondo A; Kosugi Y; Uriu K; Kimura I; Shirakawa K; Abdullahi A; Agarwal A; Ozono S; Tokunaga K; Sato K; Gupta RK; ;
    J Infect Dis; 2021 Sep; 224(6):989-994. PubMed ID: 34260717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Heavily mutated Omicron variant puts scientists on alert.
    Callaway E
    Nature; 2021 Dec; 600(7887):21. PubMed ID: 34824381
    [No Abstract]   [Full Text] [Related]  

  • 20. A Detailed Overview of Immune Escape, Antibody Escape, Partial Vaccine Escape of SARS-CoV-2 and Their Emerging Variants With Escape Mutations.
    Chakraborty C; Sharma AR; Bhattacharya M; Lee SS
    Front Immunol; 2022; 13():801522. PubMed ID: 35222380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.